cancer drug news - Search News

Daiichi Sankyo, Merck and lung cancer

Daiichi Sankyo-Merck's 'guided-missile' cancer drug meets main goal in late-stage trial

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some patients with a form of lung cancer lived without their disease progressing in a late-stage study.

MarketWatch · 3d

Daiichi Sankyo, Merck Phase 3 Lung-Cancer Study Meets Primary Endpoint

Merck & Co. and Daiichi Sankyo on Tuesday said one of the drug candidates in their multibillion-dollar collaboration has hit its main goal in a late-stage lung-cancer study. Merck and Daiichi Sankyo said a Phase 3 study evaluating patritumab deruxtecan in patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer who received prior EGFR tyrosine kinase inhibitor treatment met its primary endpoint of progression-free survival.

Seeking Alpha on MSN · 3d

Merck, Daiichi post late-stage trial win for novel lung cancer therapy

Merck (NYSE:MRK) and Daiichi Sankyo (OTCPK:DSNKY) announced Tuesday that their jointly developed lung cancer drug patritumab deruxtecan, which belongs to a new class of targeted cancer drugs called antibody-drug conjugates (ADC),

FDA expands approval of breast cancer drug Kisqali

CNBC on MSN · 1d

Novartis CEO says FDA's extended approval of breast cancer drug is a 'landmark' for the firm

Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the company recently received an extended approval for it from the U.S. Food and Drug Administration.

NBC News on MSN · 2d

FDA expands approval of breast cancer drug Kisqali to earlier-stage patients

The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease, drugmaker Novartis said Tuesday.

UPI News on MSN · 1d

FDA Expands Use of Breast Cancer Drug Kisqali

While Verzenio, a drug in the same class, has been approved to lower the risk of early breast cancer returning, it's only for people with a very high risk of recurrence. Kisqali will be available to a much broader group of patients, whose disease may not be as aggressive at the time of diagnosis, Novartis said.

AARP2d

Rx Drug Law Saves Some Cancer Patients More Than $7,000 in 2024

A recent survey from AARP found that roughly 40 percent of adults age 65-plus who are eligible for Medicare have either ...

15h

Notable Labs Pauses Implementation of Cancer Drug Volasertib Study, Announces Layoffs

Notable Labs said it is pausing implementation of the planned Phase 2 study of cancer drug Volasertib in relapsed/refractory acute myeloid leukemia. The biotechnology company also said Thursday it ...

Medscape24m

Conjugated Antibodies: Emerging Star in Ovarian Cancer Tx

Mirvetuximab soravtansine was the first ADC to show efficacy as a therapy for platinum-resistant ovarian cancer. Despite high ...

Sierra Sun Times23h

NIH Reports Bone Marrow Cancer Drug Shows Success in Treatment of Rare Blood Disorder

A clinical trial supported by the National Institutes of Health (NIH) was stopped early after researchers found sufficient ...

AbbVie Gets CHMP Backing for Elahere in Ovarian Cancer

Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer, was the key asset in AbbVie's $10.1 billion acquisition of biotech ImmunoGen that ...

Medscape2d

Case Dismissed: No Cancer Drug Delivery to Patients' Homes

Last year, the Community Oncology Alliance sued to reverse a policy that prohibits oncology practices from mailing cancer ...

Medical Xpress on MSN2d

New research could lead to better treatment for oral cancer

Dr. Chakraborty says the research opens new possibilities for oral cancer treatment, particularly addressing drug ...

5don MSN

Pfizer: Potential cachexia cancer drug shows life-saving promise

A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results